Biotechnology - Diabetes

Filter

Current filters:

Diabetes

Popular Filters

1 to 25 of 64 results

Servier gains ex-US/Japan rights to Intarcia diabetes product ITCA 650

Servier gains ex-US/Japan rights to Intarcia diabetes product ITCA 650

12-11-2014

USA-based biotech firm Intarcia Therapeutics has started a strategic partnership with French independent…

BiotechnologyDiabetesexenatide pumpFranceIntarcia TherapeuticsITCA 650LicensingServier

Kamada says study supports alpha-1 antitrypsin Glassia for type-1 diabetes

22-10-2014

Israeli biopharma company Kamada says that a comprehensive review of the data available in the literature…

BiotechnologyDiabetesGlassiaKamadaResearch

Selecta, JDRF and Sanofi collaborate to develop SVP for type 1 diabetes

Selecta, JDRF and Sanofi collaborate to develop SVP for type 1 diabetes

17-10-2014

US clinical-stage biopharma company Selecta Biosciences and JDRF have extended their joint research collaboration…

BiotechnologyDiabetesFranceResearchSanofiSelecta BiosciencesUSA

Merck Serono to partner with Lupin for emerging market exposure

Merck Serono to partner with Lupin for emerging market exposure

17-09-2014

Merck Serono, the biotech unit of Germany’s Merck KGaA, has entered a strategic partnership with Indian…

Antibiotics and Infectious diseasesBiotechnologyCardio-vascularDiabetesGermanyIndiaLicensingLupinMerck KGaAMerck Serono

Hyperion terminates DaiPep277 program due to "misconduct"

08-09-2014

Shares of Hyperion Therapeutics’ plunged 11% to $24.61 in pre-market trading today, after the company…

Andromeda BiotechAndromeda GalaxyAstronomyBiotechnologyDiabetesDiaPep277HyperionHyperion TherapeuticsResearchUSA

ViaCyte gets $20 million in deal with Janssen

ViaCyte gets $20 million in deal with Janssen

22-08-2014

Privately held US regenerative medicine company ViaCyte has entered into a rights agreement with Janssen…

BiotechnologyDiabetesEndocrine systemFinancialJanssenJohnson & JohnsonLicensingUSAVC-01ViaCyte

Positive preliminary results with Biodel's new insulin formulation in type 2 diabetes

Positive preliminary results with Biodel's new insulin formulation in type 2 diabetes

12-08-2014

Endocrine specialists Biodel has seen positive preliminary results from a Phase IIa trial of its insulin…

BIOD-531BiodelBiotechnologyDiabetesDiabetes mellitus type 2Endocrine systemHumalog MixHumulin RResearchUSA

SMC guidance on AstraZeneca’s diabetes drug and Roche’s MabThera

SMC guidance on AstraZeneca’s diabetes drug and Roche’s MabThera

08-07-2014

The Scottish Medicines Consortium (SMC) has issued guidance on Anglo-Swedish drug major AstraZeneca’s…

AstraZenecaBiotechnologydapagliflozinDiabetesMabTheraOncologyRocheUK

Janssen’s Vokanamet approved in EU for adults with type 2 diabetes

28-04-2014

The European Commission has approved US health care giant Johnson & Johnson subsidiary Janssen-Cilag’s…

BiotechnologyDiabetesEuropeJanssen-CilagJohnson & JohnsonRegulationVokanamet

Hyperion Therapeutics to broaden orphan disease pipeline with buy of Israeli firm

24-04-2014

US biotech firm Hyperion Therapeutics has entered into a definitive agreement to acquire Andromeda Biotech,…

Andromeda BiotechBiotechnologyDiabetesDiaPep277Hyperion TherapeuticsMergers & Acquisitions

Islet Sciences to acquire BHV Pharma along with diabetes and NASH products

Islet Sciences to acquire BHV Pharma along with diabetes and NASH products

13-03-2014

US biotech firm Islet Sciences says it has signed a binding letter of intent to acquire Brighthaven Ventures…

BiotechnologyDiabetesIslet SciencesMergers & AcquisitionsNephrology and Hepatologyremogliflozin

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

11-03-2014

Caisson Biotech, a wholly-owned subsidiary of Heparinex and owner of a patented heparosan-based drug…

BiotechnologyCaisson BiotechDiabetesInflammatory diseasesLicensingMetabolicsNovo Nordisk

Israel's Clal Biotech in talks to sell Andromeda unit

28-02-2014

In an announcement to the Stock Exchange, Israeli firm Clal Biotechnology Industries said that, on February…

Andromeda BiotechBiotechnologyClal BiotechnologyDiabetesDiaPep277Mergers & AcquisitionsTeva Pharmaceutical Industries

Celladon signs option agreement with Servier

24-02-2014

USA-based biotech firm Celladon has entered into an option agreement with French independent drugmaker…

BiotechnologyCelladonDiabetesLicensingServier

Positive results for MicroBiome’s NM504 in type 2 diabetes

18-02-2014

Privately-held US biotech company MicroBiome Therapeutics has released positive top-line results from…

BiotechnologyDiabetesMicroBiome TherapeuticsNM504Research

Shire sheds Dermagraft assets for $300 million in milestone payments

Shire sheds Dermagraft assets for $300 million in milestone payments

17-01-2014

Ireland-headquartered drugmaker Shire (LSE: SHP) has agreed to sell its Dermagraft (human fibroblast-derived…

BiotechnologyDermagraftDiabetesLicensingNorthern EuropeShire

DiaVacs' type 1 diabetes drug candidate gains orphan designation from FDA

DiaVacs' type 1 diabetes drug candidate gains orphan designation from FDA

06-01-2014

US clinical-stage biotech firm DiaVacs has granted orphan drug designation for its type 1 diabetes mellitus…

BiotechnologyDiabetesDiaVacsDV-0100North AmericaRegulationUSA

MannKind resubmits NDA for diabetes drug Afrezza after positive study results

MannKind resubmits NDA for diabetes drug Afrezza after positive study results

14-10-2013

MannKind has resubmitted its New Drug Application to the FDA for the marketing and sale of Afrezza Inhalation…

AfrezzaBiotechnologyDiabetesMannKindNorth AmericaRegulation

Evolva to license EV-077 to Serodus

07-10-2013

Switzerland-based Evolva Holding and Norwegian biopharma company Serodus have signed a binding term…

BiotechnologyDiabetesEV-077EvolvaLicensingNephrology and HepatologyPharmaceuticalSerodus

Approved cancer drug potentially could help treat diabetes, Stanford researchers find

16-09-2013

A pair of studies by researchers at the Stanford University School of Medicine has identified a molecular…

afliberceptBayerBiotechnologyDiabetesEyleaOncologyPharmaceuticalRegeneronResearchSanofiZaltrap

Interim results for ChemoCentryx' CCX140 fail to inspire

12-09-2013

US drug developer ChemoCentryx (Nasdaq: CCXI) announced interim data from an ongoing Phase II study in…

BiotechnologyCCX140ChemoCentryxDiabetesNephrology and HepatologyResearch

1 to 25 of 64 results

Back to top